Role of hypercoagulability and hypofibrinolysis in the progression of hepatic fibrosis

Completed

• Conditions: hepatic fibrosis; scarring of the liver; 10019654

• Registration Number: NL-OMON34971
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 292

Inclusion Criteria

1. All participants of the Rotterdam Study (cohorts RS I-5, RS II-3 and RS III-1).
- 1a. TE values >12,5 kPa in the absence of steatosis will be considered as presence of advanced fibrosis. TE values >10,5 kPa in the presence of steatosis will be considered as presence of advanced fibrosis (cases).
- 1b. TE values < 5 kPa will be considered as absence of fibrosis or presence of mild fibrosis (controls)
2. Male or female, age >=18
3. All subjects must have provided written informed consent.

Exclusion Criteria

a. Subjects with unreliable Fibroscan and/or US-examination, as evaluated by the executing technician.
b. No informed consent
c. Subjects with decompensated cirrhosis

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Prevalence of prothrombotic risk factors in patients with advanced fibrosis<br /><br>compared to controls with no or mild fibrosis. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- </p><br>